BCBS Nebraska

Does BCBS Nebraska cover Ozempic?

Quick answer · Type 2 Diabetes

BCBS Nebraska covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered (preferred drug). A1C of 6.5% or higher
  • ACA Marketplace: Covered (preferred drug). A1C of 6.5% or higher

Last verified June 2, 2026. Policy effective November 5, 2025. Source: policy-212.html. How we verify this data →

Check your card for your exact plan →

Ozempic for Type 2 Diabetes

What BCBS Nebraska requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Preferred GLP-1 - Prior Use within 90 Days

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Patient treated with a preferred agent within the past 90 days (samples not approvable)
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Preferred GLP-1 - New Start

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Ozempic is a preferred GLP-1 agent
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C >= 6.5%
  • Documentation of patient age within FDA labeling OR clinical support for off-label age use
  • Attestation that patient will not use in combination with a DPP-4 containing agent
  • Attestation that patient will not use in combination with another GLP-1 receptor agonist
  • Attestation of no FDA labeled contraindications to the requested agent
  • If prior use pathway: documentation of prior preferred agent use within past 90 days (samples not acceptable)

Quantity limits

  • 0.25mg dose, 0.5mg dose — 1 pen (2mg/1.5mL) per month
  • 1mg dose — 1 pen (4mg/3mL) per month
  • 2mg dose — 1 pen (8mg/3mL) per month
  • 1.5mg tablet, 4mg tablet, 9mg tablet — 1 tablet per day

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must have had clinical benefit with the requested agent. No re-verification of T2DM diagnosis, A1C threshold, or step therapy at renewal.

Not covered when

  • Combination use with DPP-4 containing agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to the requested agent
  • Use for non-FDA approved indications (considered investigational unless excluded by contract)

Policy note: Ozempic (injection) and Rybelsus (tablet/oral semaglutide) are both listed as preferred agents. Policy includes Ozempic tablets (1.5mg, 4mg, 9mg) as of 05-04-2026 revision at parity with Rybelsus tablets. Ozempic is a preferred agent so no step therapy through other GLP-1s is required. Non-preferred agents require trial/failure of TWO preferred agents (90 days each). Metformin step therapy was removed as of 04-01-2026.

Policy effective November 5, 2025 · verified June 2, 2026 · source: policy-212.html

ACA Marketplace

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Preferred GLP-1 - Prior Use within 90 Days

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Patient treated with a preferred agent within the past 90 days (samples not approvable)
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Preferred GLP-1 - New Start

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Ozempic is a preferred GLP-1 agent
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C >= 6.5%
  • Documentation of patient age within FDA labeling OR clinical support for off-label age use
  • Attestation that patient will not use in combination with a DPP-4 containing agent
  • Attestation that patient will not use in combination with another GLP-1 receptor agonist
  • Attestation of no FDA labeled contraindications to the requested agent
  • If prior use pathway: documentation of prior preferred agent use within past 90 days (samples not acceptable)

Quantity limits

  • 0.25mg dose, 0.5mg dose — 1 pen (2mg/1.5mL) per month
  • 1mg dose — 1 pen (4mg/3mL) per month
  • 2mg dose — 1 pen (8mg/3mL) per month
  • 1.5mg tablet, 4mg tablet, 9mg tablet — 1 tablet per day

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must have had clinical benefit with the requested agent. No re-verification of T2DM diagnosis, A1C threshold, or step therapy at renewal.

Not covered when

  • Combination use with DPP-4 containing agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to the requested agent
  • Use for non-FDA approved indications (considered investigational unless excluded by contract)

Policy note: Ozempic (injection) and Rybelsus (tablet/oral semaglutide) are both listed as preferred agents. Policy includes Ozempic tablets (1.5mg, 4mg, 9mg) as of 05-04-2026 revision at parity with Rybelsus tablets. Ozempic is a preferred agent so no step therapy through other GLP-1s is required. Non-preferred agents require trial/failure of TWO preferred agents (90 days each). Metformin step therapy was removed as of 04-01-2026.

Policy effective November 5, 2025 · verified June 2, 2026 · source: policy-212.html

Ozempic for Heart Disease Risk Reduction

What BCBS Nebraska requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Established cardiovascular disease
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in T2DM with Established CVD

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Established cardiovascular disease
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C >= 6.5%
  • Documentation of established cardiovascular disease
  • Attestation that patient will not use in combination with a DPP-4 containing agent
  • Attestation that patient will not use in combination with another GLP-1 receptor agonist
  • Attestation of no FDA labeled contraindications to the requested agent

Quantity limits

  • 0.25mg dose, 0.5mg dose — 1 pen (2mg/1.5mL) per month
  • 1mg dose — 1 pen (4mg/3mL) per month
  • 2mg dose — 1 pen (8mg/3mL) per month

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must have had clinical benefit with the requested agent.

Not covered when

  • Combination use with DPP-4 containing agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to the requested agent

Policy note: Policy states Ozempic is FDA approved to reduce risk of major adverse cardiovascular events in adults with T2DM and established CVD. The policy criteria do not separate CV risk reduction from diabetes criteria in explicit steps — the same general pathway applies with T2DM diagnosis and established CVD as the indication. Specific qualifying CV events (MI, stroke, PAD) are not enumerated in this policy. Since Ozempic is preferred, no GLP-1 step therapy is required.

Policy effective November 5, 2025 · verified June 2, 2026 · source: policy-212.html

ACA Marketplace

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Established cardiovascular disease
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in T2DM with Established CVD

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Established cardiovascular disease
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C >= 6.5%
  • Documentation of established cardiovascular disease
  • Attestation that patient will not use in combination with a DPP-4 containing agent
  • Attestation that patient will not use in combination with another GLP-1 receptor agonist
  • Attestation of no FDA labeled contraindications to the requested agent

Quantity limits

  • 0.25mg dose, 0.5mg dose — 1 pen (2mg/1.5mL) per month
  • 1mg dose — 1 pen (4mg/3mL) per month
  • 2mg dose — 1 pen (8mg/3mL) per month

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must have had clinical benefit with the requested agent.

Not covered when

  • Combination use with DPP-4 containing agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to the requested agent

Policy note: Policy states Ozempic is FDA approved to reduce risk of major adverse cardiovascular events in adults with T2DM and established CVD. The policy criteria do not separate CV risk reduction from diabetes criteria in explicit steps — the same general pathway applies with T2DM diagnosis and established CVD as the indication. Specific qualifying CV events (MI, stroke, PAD) are not enumerated in this policy. Since Ozempic is preferred, no GLP-1 step therapy is required.

Policy effective November 5, 2025 · verified June 2, 2026 · source: policy-212.html

Why Ozempic requests get denied by BCBS Nebraska

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Ozempic and Wegovy are the same molecule with different approved uses; a request for Ozempic under a diagnosis that matches Wegovy is routinely denied.
  2. No recent A1C result on file.

Frequently asked questions

Does BCBS Nebraska cover Ozempic?
BCBS Nebraska covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
How long does a Ozempic approval last with BCBS Nebraska?
Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does BCBS Nebraska require to renew Ozempic?
Patient must have had clinical benefit with the requested agent. No re-verification of T2DM diagnosis, A1C threshold, or step therapy at renewal.
How current is this information?
This page reflects BCBS Nebraska's written policy as of November 5, 2025, last verified against the source document on June 2, 2026.

Other medications under BCBS Nebraska

Ozempic coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Nebraska's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.